A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users

被引:127
|
作者
Garfein, Richard S.
Golub, Elizabeth T.
Greenberg, Alan E.
Hagan, Holly
Hanson, Debra L.
Hudson, Sharon M.
Kapadia, Farzana
Latka, Mary H.
Ouellet, Lawrence.
Purcell, David W.
Strathdee, Steffanie A.
Thiede, Hanne
机构
[1] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Natl Res & Dev Inst, New York, NY USA
[4] Hlth Res Assoc, Los Angeles, CA USA
[5] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA
[6] Univ Illinois, Sch Publ Hlth, Chicago, IL USA
[7] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[8] Publ Hlth Seattle & King Cty, Seattle, WA USA
[9] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA
关键词
hepatitis C virus; HIV; injection drug use; peer education; randomized controlled trial; young adult;
D O I
10.1097/QAD.0b013e32823f9066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate whether a behavioral intervention, which taught peer education skills, could reduce injection and sexual risk behaviors associated with primary HIV and hepatitis C virus infection (HCV) among young injection drug users (IDU). Design: We conducted a randomized controlled trial involving HIV and HCV antibody-negative IDU, aged 15-30 years, recruited in five United States cities. A six-session, small-group, cognitive behavioral, skills-building intervention in which participants were taught peer education skills (n = 431) was compared with a time-equivalent attention control (n = 423). Baseline visits included interviews for sociodemographic, psychosocial, and behavioral factors during the previous 3 months; HIV and HCV antibody testing; and pre/posttest counselling. Procedures were repeated 3 and 6 months postintervention. Results: The intervention produced a 29% greater decline in overall injection risk 6 months postintervention relative to the control [proportional odds ratio 0.71; 95% confidence limit (CL) 0.52, 0.971, and a 76% decrease compared with baseline. Decreases were also observed for sexual risk behaviors, but they did not differ by trial arm. Overall HCV infection incidence (18.4/100 person-years) did not differ significantly across trial arms (relative risk 1.15; 95% CL 0.72, 1.82). No HIV seroconversions were observed. Conclusion: Interventions providing information, enhancing risk-reduction skills, and motivating behavior change through peer education training can reduce injection risk behaviors, although risk elimination might be necessary to prevent HCV transmission. (C) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1923 / 1932
页数:10
相关论文
共 50 条
  • [41] Risk behaviors and hepatitis C virus (HCV) infection among new- and long-term injection drug users (IDUs)
    Oliveira, M. L. A.
    Oliveira, S. A. N.
    Telles, P. R.
    Hacker, M.
    Miguel, J. C.
    Do O, K. M. R.
    Yoshida, C. F. T.
    Bastos, F. I.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S202 - S203
  • [42] Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness
    Korthuis, P. Todd
    Feaster, Daniel J.
    Gomez, Zoilyn L.
    Das, Moupali
    Tross, Susan
    Wiest, Katharina
    Douaihy, Antoine
    Mandler, Raul N.
    Sorensen, James L.
    Colfax, Grant
    McCarty, Dennis
    Cohen, Stephanie E.
    Penn, Patricia E.
    Lape, Diane
    Metsch, Lisa R.
    ADDICTIVE BEHAVIORS, 2012, 37 (04) : 552 - 555
  • [43] A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C
    Latka, Mary H.
    Hagan, Holly
    Kapadia, Farzana
    Golub, Elizabeth T.
    Bonner, Sebastian
    Campbell, Jennifer V.
    Coady, Micaela H.
    Garfein, Richard S.
    Pu, Minya
    Thomas, Dave L.
    Thiel, Thelma K.
    Strathdee, Steffanie A.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2008, 98 (05) : 853 - 861
  • [44] Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities
    Hagan, H
    Latka, MH
    Campbell, JV
    Golub, ET
    Garfein, RS
    Thomas, DA
    Kapadia, F
    Strathdee, SA
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (05) : 669 - 672
  • [45] Eligibility for treatment of hepatitis C virus infection among young injection drug users in three US cities
    Hagan, H
    Campbell, J
    Garfein, R
    Latka, M
    Strathdee, S
    Thomas, D
    Golub, E
    HEPATOLOGY, 2005, 42 (04) : 693A - 693A
  • [46] Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco
    Hahn, JA
    Page-Shafer, K
    Lum, P
    Ochoa, K
    Moss, AR
    HEPATOLOGY, 2001, 34 (01) : 180 - 187
  • [47] Coinfection with HIV and hepatitis C virus among injection drug users in southern China
    Garten, RJ
    Zhang, JB
    Lai, SH
    Liu, W
    Chen, J
    Yu, XF
    CLINICAL INFECTIOUS DISEASES, 2005, 41 : S18 - S24
  • [48] Hepatitis C virus seroconversion among young injection drug users: Relationships and risks
    Hahn, JA
    Page-Shafer, K
    Lum, PJ
    Bourgois, P
    Stein, E
    Evans, JL
    Busch, MP
    Tobler, LH
    Phelps, B
    Moss, AR
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (11): : 1558 - 1564
  • [49] Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy
    Quaglio, G
    Lugoboni, F
    Pajusco, B
    Sarti, M
    Talamini, G
    Lechi, A
    Mezzelani, P
    Jarlais, DCD
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) : 33 - 40
  • [50] Treatment for hepatitis C virus infection among current injection drug users in Australia
    Matthews, G
    Kronborg, IJ
    Dore, GJ
    CLINICAL INFECTIOUS DISEASES, 2005, 40 : S325 - S329